Dynavax Technologies Corporation (NASDAQ:DVAX) has a beta value of 1.16 and has seen 2,440,950 shares traded in the recent trading session. The company, currently valued at $951.97 Million, closed the recent trade at $8.75 per share which meant it gained $0.2 on the day or 3.06% during that session. The DVAX stock price is -11.31% off its 52-week high price of $9.74 and 79.43% above the 52-week low of $1.8. If we look at the company’s 10-day average daily trading volume, we find that it stood at 9.79 Million shares traded. The 3-month trading volume is 6.04 Million shares.

The consensus among analysts is that Dynavax Technologies Corporation (DVAX) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 4 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.24.

Dynavax Technologies Corporation (NASDAQ:DVAX) trade information

Sporting 4.36% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Jun 26 when the DVAX stock price touched $9.74-1 or saw a rise of 10.27%. Year-to-date, Dynavax Technologies Corporation shares have moved 52.8%, while the 5-day performance has seen it change 18.99%. Over the past 30 days, the shares of Dynavax Technologies Corporation (NASDAQ:DVAX) have changed 42.81%. Short interest in the company has seen 12.58 Million shares shorted with days to cover at 2.08.

Wall Street analysts have a consensus price target for the stock at $14, which means that the shares’ value could jump 60% from current levels. The projected low price target is $10 while the price target rests at a high of $20. In that case, then, we find that the current price level is +128.57% off the targeted high while a plunge would see the stock lose 14.29% from current levels.

Dynavax Technologies Corporation (DVAX) estimates and forecasts

Figures show that Dynavax Technologies Corporation shares have underperformed across the wider relevant industry. The company’s shares have gained +41.74% over the past 6 months, with this year growth rate of -50.27%, compared to 9.3% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 63.6% and 57.1% for the next quarter. Revenue growth from the last financial year stood is estimated to be +8.9%.

3 analysts offering their estimates for the company have set an average revenue estimate of $5.55 Million for the current quarter. 3 have an estimated revenue figure of $8.7 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $8.3 Million and $10.57 Million respectively for this quarter and the next, and analysts expect sales will grow by -33.1% for the current quarter and -17.7% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +8.9% over the past 5 years. Earnings growth for 2020 is a modest +15.1% while over the next 5 years, the company’s earnings are expected to increase by 0%.